Catabasis Pharmaceuticals

Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Therapy, Plasma, Abdomen, Catabasis Pharmaceuticals, IND, Degenerative disease, NASDAQ, Disease, Swelling, Quelli che... il Calcio, Hereditary angioedema, D, Asthma, COVID-19, Instagram, Face, Facebook, Forward-looking statement, Neonatal Fc receptor, Annual report, Bradykinin, File, Twitter, Acquisition, Plasma kallikrein, YTE, Company, Research, NORD, Nasdaq, Half-life, LinkedIn, Lanadelumab, SEC, Hope, Pharmacy, Drug discovery, American College of Allergy, Asthma and Immunology, Investigational New Drug, Review, National Organ Transplant Act of 1984, ACAAI, Genetic disorder, Time, Patient, Risk, FDA, American College, Allergy, Fine chemical, Pharmaceutical industry, Lithium, Animal, Reinsurance, Air cargo

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Our new company name, Astria, embodies our commitment to put patients first in all that we do.
  • On September 8, 2021, the Company formally changed its name from Catabasis Pharmaceuticals to Astria Therapeutics.
  • Cash Position: As of September 30, 2021, Astria had cash and cash equivalents of $131.8 million, compared to $139.5 million as of June 30, 2021.

Nimbus Therapeutics Appoints Ian Sanderson, MBA, as Chief Financial Officer

Retrieved on: 
Tuesday, September 21, 2021
Technology, Biotechnology, Nanotechnology, Health, Therapy, Catabasis Pharmaceuticals, Cowen Inc., Wharton School of the University of Pennsylvania, Pathology, CPA, Financial management, University, Company, LLC, Williams College, Growth, Leadership, MBA, Research, Wendell Pritchett, Protein, Pharmaceutical industry, Management

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Ian Sanderson, MBA, as Chief Financial Officer.

Key Points: 
  • Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Ian Sanderson, MBA, as Chief Financial Officer.
  • He succeeds Holly Whittemore, CPA, who will transition to the newly created role of Chief Accounting Officer, reporting to Mr. Sanderson.
  • Mr. Sanderson joins Nimbus from Boston Pharmaceuticals, where he served as Chief Financial Officer.
  • He previously served as Chief Financial Officer at Catabasis Pharmaceuticals, where he led the companys re-positioning initiative and successful IPO.

Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, August 9, 2021
Biotechnology, Pharmaceutical, Health, Transfer, Investment, Bradykinin, CATB, Kallikrein, Research, COVID-19, LLC, Review, FDA, Half-life, Pharmacy, Time, Genetic disorder, Acquisition, Annual general meeting, Clinical trial, Quelli che... il Calcio, File, Face, Catabasis Pharmaceuticals, Abdomen, Plasma, Hope, Patient, NASDAQ, Investigational New Drug, SEC, Risk, Nasdaq, Forward-looking statement, Hereditary angioedema, D, Plasma kallikrein, Exercise, HAE, IND, CUSIP, Book, Drug discovery, Swelling, Physician, Annual report, Company, Pharmaceutical industry, Vaccine, Security (finance), Animal, Aquaculture, Tutoring

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
  • Catabasis expects that the results of this trial, if positive, could provide clinical proof of concept for the activity and plasma half-life improvements for QLS-215.
  • Stockholders of the Company approved the conversion of the Companys non-voting Series X Preferred Stock at the 2021 Annual Meeting held on June 2, 2021.
  • Cash Position: As of June 30, 2021, Catabasis had cash, cash equivalents and short-term investments of $139.5 million, compared to $146.9 million as of March 31, 2021.

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Complement deficiency, Organ systems, Medical specialties, Angioedema, Catabasis Pharmaceuticals, Hereditary angioedema, Clinical medicine, Kinin–kallikrein system, Hae, QLS, Kallikrein

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.
  • The session entitled HAE There- Development Landscape in Hereditary Angioedema (HAE) will include an overview of the HAE treatment landscape, information about Catabasiss lead program QLS-215, and a Q&A session.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Medical specialties, Clinical medicine, Complement deficiency, Biotechnology, Catabasis Pharmaceuticals, Angioedema, Kinin–kallikrein system, Hereditary angioedema, Kallikrein, Monoclonal antibody, Biopharmaceutical

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference.
  • The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Retrieved on: 
Friday, May 14, 2021
Biotechnology, Pharmaceutical, Health, Life sciences, Medical specialties, Clinical medicine, Complement deficiency, Biotechnology, Angioedema, Catabasis Pharmaceuticals, Hereditary angioedema, Monoclonal antibody, Biopharmaceutical, QLS, Kallikrein

b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:\nOppenheimer Rare and Orphan Disease Summit.

Key Points: 
  • b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:\nOppenheimer Rare and Orphan Disease Summit.
  • Presentations will be available on-demand on May 21, 2021.\nJefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET.\nWebcasts of the events can be accessed from the investors section of www.catabasis.com .
  • Archived replays will be available for 30 days following the event.\nAt Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005065/en/\n'

 Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, May 13, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Anatomy, Branches of biology, Muscular system, Muscular dystrophy, Catabasis Pharmaceuticals, Dystrophin, Muscle fibers, Skeletal muscle, EDG-5506 for DMD and BMD, Edgewise Therapeutics, EDG-5506 FOR DMD AND BMD, EDGEWISE THERAPEUTICS

Gross proceeds of the offering, before deducting the underwriting discount and commissions and other estimated offering expenses, were $202.4 million.

Key Points: 
  • Gross proceeds of the offering, before deducting the underwriting discount and commissions and other estimated offering expenses, were $202.4 million.
  • In March 2021, EDG-5506 advanced into the Multiple Ascending Dose (MAD) portion of the study, having successfully completed the Single Ascending Dose (SAD) portion of the study.
  • The results build on previous reports and suggest that slow skeletal muscle fibers do not appear to leak muscle proteins associated with muscle injury and damage in DMD and BMD.
  • In February 2021, Edgewise also sponsored the Jett Foundation\xe2\x80\x99s Rare Disease Day Celebration.\nIn May 2021, Edgewise appointed Joanne Donovan, M.D., Ph.D., as its Chief Medical Officer (CMO), following her most recent tenure as CMO and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals.

 Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, May 13, 2021
Biotechnology, Pharmaceutical, Health, Catabasis Pharmaceuticals

b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.\n\xe2\x80\x9cWe see Catabasis as being in a strong position for 2021 thanks to the acquisition of Quellis and the concurrent financing earlier this year.

Key Points: 
  • b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.\n\xe2\x80\x9cWe see Catabasis as being in a strong position for 2021 thanks to the acquisition of Quellis and the concurrent financing earlier this year.
  • The acquisition cost allocated to acquired IPR&D with no alternative future use was recorded as expense at the acquisition date.
  • New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
  • These forward-looking statements should not be relied upon as representing the Company\xe2\x80\x99s views as of any date subsequent to the date hereof.\nThree Months Ended March 31,\n'

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 11, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Catabasis Pharmaceuticals, Pharmaceutical industry in China, Health care, Health

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
  • Subsequently, Catabasis expects to initiate a Phase 1b/2 trial in patients affected by HAE in 2023 with initial results anticipated by the end of 2023.
  • Catabasis expects to seek stockholder approval at its 2021 Annual Meeting of Stockholders, which Catabasis has scheduled for June 2, 2021.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare diseases.

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   

Retrieved on: 
Tuesday, March 2, 2021
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Complement deficiency, Catabasis Pharmaceuticals, Angioedema, Medical specialties, Hereditary angioedema, Clinical medicine, Health

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:
    H.C. Wainwright Global Life Sciences Conference.
  • Catabasis is also participating in Guggenheim Healthcare Talks, 2021 Genomic Medicines & Rare Disease, on April 1, 2021.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.